• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加勒比地区1型脊髓性肌萎缩症:来自多米尼加共和国的首例病例报告。

Spinal muscular atrophy type 1 in the Caribbean: the first case report from the Dominican Republic.

作者信息

Martín-Sanz María Belén, Lucas-Muñoz Delvis, Colomé-Hidalgo Manuel

机构信息

Research Group of Humanities and Qualitative Research in Health Science, King Juan Carlos University, Alcorcón, Spain.

Hospital Pediátrico Dr. Hugo Mendoza, Santo Domingo, Dominican Republic.

出版信息

Front Neurosci. 2025 Jan 8;18:1476977. doi: 10.3389/fnins.2024.1476977. eCollection 2024.

DOI:10.3389/fnins.2024.1476977
PMID:39844848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11751030/
Abstract

Spinal muscular atrophy (SMA) is a progressive genetic neuromuscular condition affecting spinal motor neurons. The underlying cause of SMA is deletions or mutations in the SMN gene. It is classified into five variants based on age and clinical manifestations of the patient. In this report, we present the case discovery of a four-month-old male patient with SMA type 1, presenting with generalized hypotonia and regression of acquired neurodevelopmental milestones. Our study aims to illustrate, through a case report, the clinical analysis, therapeutic interventions, and progression until the patient's demise. This aims to share the challenges in managing such patients and the strategies employed in their care plan. By documenting this case, our goal is to contribute to the understanding of SMA type 1 and emphasize the ongoing need for learning effective care strategies.

摘要

脊髓性肌萎缩症(SMA)是一种影响脊髓运动神经元的进行性遗传性神经肌肉疾病。SMA的根本原因是SMN基因的缺失或突变。根据患者的年龄和临床表现,它被分为五个亚型。在本报告中,我们介绍了一例1型SMA的4个月大男性患者的病例发现,该患者表现为全身肌张力减退和已获得的神经发育里程碑倒退。我们的研究旨在通过病例报告说明临床分析、治疗干预以及直至患者死亡的疾病进展情况。这旨在分享管理此类患者的挑战以及护理计划中采用的策略。通过记录此病例,我们的目标是促进对1型SMA的理解,并强调持续学习有效护理策略的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/412a1b834d05/fnins-18-1476977-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/0b4f509297fa/fnins-18-1476977-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/d63d71897c6b/fnins-18-1476977-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/40e5c1fbda8a/fnins-18-1476977-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/412a1b834d05/fnins-18-1476977-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/0b4f509297fa/fnins-18-1476977-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/d63d71897c6b/fnins-18-1476977-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/40e5c1fbda8a/fnins-18-1476977-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d391/11751030/412a1b834d05/fnins-18-1476977-g004.jpg

相似文献

1
Spinal muscular atrophy type 1 in the Caribbean: the first case report from the Dominican Republic.加勒比地区1型脊髓性肌萎缩症:来自多米尼加共和国的首例病例报告。
Front Neurosci. 2025 Jan 8;18:1476977. doi: 10.3389/fnins.2024.1476977. eCollection 2024.
2
Generalized Hypotonia Revealing Spinal Muscular Atrophy Type 2: The First Case Reported From the Dominican Republic and a Review of the Literature.以全身性肌张力减退为表现的2型脊髓性肌萎缩症:多米尼加共和国首例病例报告及文献综述
Cureus. 2020 Nov 12;12(11):e11464. doi: 10.7759/cureus.11464.
3
Multidisciplinary approach on divergent outcomes in spinal muscular atrophies: comparing DYNC1H1 and SMN1 gene mutations.脊髓性肌萎缩症不同结局的多学科方法:比较 DYNC1H1 和 SMN1 基因突变。
Neurol Sci. 2024 Sep;45(9):4583-4588. doi: 10.1007/s10072-024-07613-6. Epub 2024 May 28.
4
Migrating atelectasis in Werdnig-Hoffmann disease: pulmonary manifestations in two cases of spinal muscular atrophy type 1.韦尼克-霍夫曼病中的迁徙性肺不张:两例1型脊髓性肌萎缩症的肺部表现
Pediatr Pulmonol. 1999 Aug;28(2):149-53. doi: 10.1002/(sici)1099-0496(199908)28:2<149::aid-ppul12>3.0.co;2-w.
5
[Molecular basis of spinal muscular atrophy: th SMN gene].[脊髓性肌萎缩症的分子基础:SMN基因]
Neurologia. 2000 Nov;15(9):393-400.
6
Spinal muscular atrophies.脊髓性肌萎缩症
Pediatr Clin North Am. 2015 Jun;62(3):743-66. doi: 10.1016/j.pcl.2015.03.010. Epub 2015 Apr 11.
7
Two Japanese Patients With SMA Type 1 Suggest that Axonal-SMN May Not Modify the Disease Severity.两名患有1型脊髓性肌萎缩症的日本患者表明,轴突性生存运动神经元蛋白可能不会改变疾病严重程度。
Pediatr Neurol. 2015 Jun;52(6):638-41. doi: 10.1016/j.pediatrneurol.2015.02.023. Epub 2015 Feb 28.
8
New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?脊髓性肌萎缩症的新疗法和发展疗法:从基因型到表型再到治疗,我们现在处于什么位置?
Int J Mol Sci. 2020 May 7;21(9):3297. doi: 10.3390/ijms21093297.
9
Therapeutic strategies for spinal muscular atrophy: SMN and beyond.脊髓性肌萎缩症的治疗策略:生存运动神经元蛋白及其他
Dis Model Mech. 2017 Aug 1;10(8):943-954. doi: 10.1242/dmm.030148.
10
Advances and limitations for the treatment of spinal muscular atrophy.脊髓性肌萎缩症治疗的进展与局限。
BMC Pediatr. 2022 Nov 3;22(1):632. doi: 10.1186/s12887-022-03671-x.

本文引用的文献

1
Exploring variability in cognitive functioning in patients with spinal muscular atrophy: a scoping review.探索脊髓性肌萎缩症患者认知功能的变异性:范围综述。
Neurol Sci. 2024 Aug;45(8):3699-3710. doi: 10.1007/s10072-024-07503-x. Epub 2024 Apr 6.
2
Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.诺西那生钠和利司扑兰治疗脊髓性肌萎缩症的安全性和有效性:一项随机对照试验的系统评价和荟萃分析
Brain Sci. 2023 Oct 7;13(10):1419. doi: 10.3390/brainsci13101419.
3
Spinal Muscular Atrophy Type 1 Survival Without New Pharmacotherapies: Two Treatment Paradigms.
脊髓性肌萎缩症 1 型在没有新的药物治疗情况下的生存:两种治疗模式。
Am J Phys Med Rehabil. 2024 Mar 1;103(3):233-237. doi: 10.1097/PHM.0000000000002354. Epub 2023 Oct 25.
4
Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.脊髓性肌萎缩症自然史的系统文献回顾:运动功能、脊柱侧凸和挛缩。
Neurology. 2023 Nov 21;101(21):e2103-e2113. doi: 10.1212/WNL.0000000000207878. Epub 2023 Oct 9.
5
Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.脊髓性肌萎缩症患者的医疗资源利用和费用:来自回顾性美国理赔数据库分析的结果。
Adv Ther. 2023 Oct;40(10):4589-4605. doi: 10.1007/s12325-023-02621-y. Epub 2023 Aug 16.
6
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment.脊髓性肌萎缩症:诊断和治疗的过去、现在和未来。
Int J Mol Sci. 2023 Jul 26;24(15):11939. doi: 10.3390/ijms241511939.
7
Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).脊髓性肌萎缩症(SMA)的基因治疗:关于onasemnogene abeparvovec(Zolgensma)的当前挑战和安全性考量的综述
Cureus. 2023 Mar 15;15(3):e36197. doi: 10.7759/cureus.36197. eCollection 2023 Mar.
8
Rarecare: A policy perspective on the burden of rare diseases on caregivers in Latin America.罕见关怀:拉丁美洲罕见病患者照顾者负担的政策视角。
Front Public Health. 2023 Mar 2;11:1127713. doi: 10.3389/fpubh.2023.1127713. eCollection 2023.
9
Carer burden in rare inherited diseases: a literature review and conceptual model.罕见遗传性疾病照护者负担:文献回顾与概念模型。
Orphanet J Rare Dis. 2022 Dec 9;17(1):428. doi: 10.1186/s13023-022-02561-w.
10
Advances and limitations for the treatment of spinal muscular atrophy.脊髓性肌萎缩症治疗的进展与局限。
BMC Pediatr. 2022 Nov 3;22(1):632. doi: 10.1186/s12887-022-03671-x.